array(40) {
  [0]=>
  string(4) "8974"
  ["article_id"]=>
  string(4) "8974"
  [1]=>
  string(55) "Marken: COVID-19 shaking up clinical trial supply chain"
  ["article_title"]=>
  string(55) "Marken: COVID-19 shaking up clinical trial supply chain"
  [2]=>
  string(150) "With the pandemic causing unprecedented global interruptions to the clinical trial supply chain, the logistics company says bold solutions are needed."
  ["short_description"]=>
  string(150) "With the pandemic causing unprecedented global interruptions to the clinical trial supply chain, the logistics company says bold solutions are needed."
  [3]=>
  string(150) "With the pandemic causing unprecedented global interruptions to the clinical trial supply chain, the logistics company says bold solutions are needed."
  ["description"]=>
  string(150) "With the pandemic causing unprecedented global interruptions to the clinical trial supply chain, the logistics company says bold solutions are needed."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(151) "https://www.outsourcing-pharma.com/Article/2020/04/02/COVID-19-disrupts-clinical-trial-supply-chain?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(151) "https://www.outsourcing-pharma.com/Article/2020/04/02/COVID-19-disrupts-clinical-trial-supply-chain?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2030-04-02 23:25:00"
  ["add_date"]=>
  string(19) "2030-04-02 23:25:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2020-04-12 16:42:24"
  ["create_at"]=>
  string(19) "2020-04-12 16:42:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9340"
  ["article_id"]=>
  string(4) "9340"
  [1]=>
  string(86) "Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies"
  ["article_title"]=>
  string(86) "Capital and Business Alliance Formed Between MEDIROM MOTHER Labs and NFES Technologies"
  [2]=>
  string(150) "NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen NFES Group Selected as Lead Investor in Series A Round Valued at 9 Bill"
  ["short_description"]=>
  string(150) "NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen NFES Group Selected as Lead Investor in Series A Round Valued at 9 Bill"
  [3]=>
  string(168) "NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen 
NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen
"
  ["description"]=>
  string(168) "NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen 
NFES Group Selected as Lead Investor in Series A Round Valued at 9 Billion Yen
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(158) "https://www.globenewswire.com/news-release/2024/08/24/2935125/0/en/Capital-and-Business-Alliance-Formed-Between-MEDIROM-MOTHER-Labs-and-NFES-Technologies.html"
  ["blog_url"]=>
  string(158) "https://www.globenewswire.com/news-release/2024/08/24/2935125/0/en/Capital-and-Business-Alliance-Formed-Between-MEDIROM-MOTHER-Labs-and-NFES-Technologies.html"
  [15]=>
  string(19) "2024-08-24 09:12:00"
  ["add_date"]=>
  string(19) "2024-08-24 09:12:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9341"
  ["article_id"]=>
  string(4) "9341"
  [1]=>
  string(68) "Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
  ["article_title"]=>
  string(68) "Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
  [2]=>
  string(158) "SAN DIEGO, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused o"
  ["short_description"]=>
  string(158) "SAN DIEGO, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused o"
  [3]=>
  string(704) "
SAN DIEGO, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its common stock to one new non-executive employee under the Company’s 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
"
  ["description"]=>
  string(704) "
SAN DIEGO, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on August 22, 2024, the Board of Directors granted a non-qualified stock option award to purchase 40,000 shares of its common stock to one new non-executive employee under the Company’s 2024 Inducement Equity Incentive Plan (the “2024 Inducement Plan”). The stock options were granted as an inducement material to the employee entering into employment with Skye in accordance with Nasdaq Listing Rule 5635(c)(4).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(138) "https://www.globenewswire.com/news-release/2024/08/23/2935114/0/en/Skye-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  ["blog_url"]=>
  string(138) "https://www.globenewswire.com/news-release/2024/08/23/2935114/0/en/Skye-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  [15]=>
  string(19) "2024-08-24 06:45:00"
  ["add_date"]=>
  string(19) "2024-08-24 06:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9342"
  ["article_id"]=>
  string(4) "9342"
  [1]=>
  string(82) "Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q"
  ["article_title"]=>
  string(82) "Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q"
  [2]=>
  string(166) "BOCA RATON, Fla., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a c"
  ["short_description"]=>
  string(166) "BOCA RATON, Fla., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a c"
  [3]=>
  string(1079) "
BOCA RATON, Fla., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
"
  ["description"]=>
  string(1079) "
BOCA RATON, Fla., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 (the “Form 10-Q”), the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”). Nasdaq has informed the Company that it has until October 21, 2024, to submit a plan to regain compliance with the Rule. If Nasdaq approves the Company’s plan, it has the discretion to grant the Company an extension of up to 180 calendar days from the due date of the Form 10-Q (or until February 17, 2025) to regain compliance.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(152) "https://www.globenewswire.com/news-release/2024/08/23/2935094/0/en/Entero-Therapeutics-Inc-Receives-Nasdaq-Notification-Regarding-Delayed-Form-10-Q.html"
  ["blog_url"]=>
  string(152) "https://www.globenewswire.com/news-release/2024/08/23/2935094/0/en/Entero-Therapeutics-Inc-Receives-Nasdaq-Notification-Regarding-Delayed-Form-10-Q.html"
  [15]=>
  string(19) "2024-08-24 05:00:00"
  ["add_date"]=>
  string(19) "2024-08-24 05:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9343"
  ["article_id"]=>
  string(4) "9343"
  [1]=>
  string(50) "Cingulate Announces Adjournment of Special Meeting"
  ["article_title"]=>
  string(50) "Cingulate Announces Adjournment of Special Meeting"
  [2]=>
  string(166) "KANSAS CITY, Kan., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical compa"
  ["short_description"]=>
  string(166) "KANSAS CITY, Kan., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical compa"
  [3]=>
  string(581) "
KANSAS CITY, Kan., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.
"
  ["description"]=>
  string(581) "
KANSAS CITY, Kan., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), (“Cingulate” or the “Company”), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that it has adjourned its Special Meeting of Stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on all proposals.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(122) "https://www.globenewswire.com/news-release/2024/08/23/2935093/0/en/Cingulate-Announces-Adjournment-of-Special-Meeting.html"
  ["blog_url"]=>
  string(122) "https://www.globenewswire.com/news-release/2024/08/23/2935093/0/en/Cingulate-Announces-Adjournment-of-Special-Meeting.html"
  [15]=>
  string(19) "2024-08-24 04:45:00"
  ["add_date"]=>
  string(19) "2024-08-24 04:45:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9344"
  ["article_id"]=>
  string(4) "9344"
  [1]=>
  string(69) "Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
  ["article_title"]=>
  string(69) "Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)"
  [2]=>
  string(150) "BRISBANE, Calif., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing fir"
  ["short_description"]=>
  string(150) "BRISBANE, Calif., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing fir"
  [3]=>
  string(517) "
BRISBANE, Calif., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 60,000 shares of its common stock under the Company’s 2023 Inducement Plan.
"
  ["description"]=>
  string(517) "
BRISBANE, Calif., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 60,000 shares of its common stock under the Company’s 2023 Inducement Plan.
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(139) "https://www.globenewswire.com/news-release/2024/08/23/2935084/0/en/Tempest-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  ["blog_url"]=>
  string(139) "https://www.globenewswire.com/news-release/2024/08/23/2935084/0/en/Tempest-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  [15]=>
  string(19) "2024-08-24 04:30:00"
  ["add_date"]=>
  string(19) "2024-08-24 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9345"
  ["article_id"]=>
  string(4) "9345"
  [1]=>
  string(83) "Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
  ["article_title"]=>
  string(83) "Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
  [2]=>
  string(152) "CAMBRIDGE, Mass., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused "
  ["short_description"]=>
  string(152) "CAMBRIDGE, Mass., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused "
  [3]=>
  string(706) "
CAMBRIDGE, Mass., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
"
  ["description"]=>
  string(706) "
CAMBRIDGE, Mass., Aug.  23, 2024  (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(153) "https://www.globenewswire.com/news-release/2024/08/23/2935086/0/en/Fulcrum-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  ["blog_url"]=>
  string(153) "https://www.globenewswire.com/news-release/2024/08/23/2935086/0/en/Fulcrum-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html"
  [15]=>
  string(19) "2024-08-24 04:30:00"
  ["add_date"]=>
  string(19) "2024-08-24 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:06"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:06"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9346"
  ["article_id"]=>
  string(4) "9346"
  [1]=>
  string(117) "Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q"
  ["article_title"]=>
  string(117) "Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q"
  [2]=>
  string(150) "PROVIDENCE, Rhode Island, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it recei"
  ["short_description"]=>
  string(150) "PROVIDENCE, Rhode Island, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it recei"
  [3]=>
  string(637) "
PROVIDENCE, Rhode Island, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
"
  ["description"]=>
  string(637) "
PROVIDENCE, Rhode Island, Aug.  23, 2024  (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), today announced that on August 19, 2024, it received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic reports with the Securities and Exchange Commission (the “SEC”).
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(187) "https://www.globenewswire.com/news-release/2024/08/23/2935087/0/en/Ocean-Biomedical-Inc-Announces-Receipt-of-Notice-from-Nasdaq-Regarding-Late-Filing-of-Quarterly-Report-on-Form-10-Q.html"
  ["blog_url"]=>
  string(187) "https://www.globenewswire.com/news-release/2024/08/23/2935087/0/en/Ocean-Biomedical-Inc-Announces-Receipt-of-Notice-from-Nasdaq-Regarding-Late-Filing-of-Quarterly-Report-on-Form-10-Q.html"
  [15]=>
  string(19) "2024-08-24 04:30:00"
  ["add_date"]=>
  string(19) "2024-08-24 04:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:07"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:07"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "9347"
  ["article_id"]=>
  string(4) "9347"
  [1]=>
  string(118) "SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome"
  ["article_title"]=>
  string(118) "SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome"
  [2]=>
  string(150) "SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Avi"
  ["short_description"]=>
  string(150) "SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Avi"
  [3]=>
  string(223) "
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel 
"
  ["description"]=>
  string(223) "
SciSparc to conduct the trial at the Yale Child Study Center at the Yale School of Medicine in the USA, Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel 
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "25"
  ["rss_id"]=>
  string(2) "25"
  [14]=>
  string(190) "https://www.globenewswire.com/news-release/2024/08/23/2935076/0/en/SciSparc-Submitted-IND-Application-to-the-FDA-for-SCI-110-Phase-IIb-Clinical-Trial-for-Patients-with-Tourette-Syndrome.html"
  ["blog_url"]=>
  string(190) "https://www.globenewswire.com/news-release/2024/08/23/2935076/0/en/SciSparc-Submitted-IND-Application-to-the-FDA-for-SCI-110-Phase-IIb-Clinical-Trial-for-Patients-with-Tourette-Syndrome.html"
  [15]=>
  string(19) "2024-08-24 04:09:00"
  ["add_date"]=>
  string(19) "2024-08-24 04:09:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2024-08-24 15:24:07"
  ["create_at"]=>
  string(19) "2024-08-24 15:24:07"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}